Artugen Therapeutics announces first patient dosed with ART24

This article was originally published here

The advancement of ART24 into the Phase 1 clinical trial was based on its favorable profile exhibited in pre-clinical safety testing, as well as its demonstration of potent

The post Artugen Therapeutics announces first patient dosed with ART24 appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply